What hormone replacement therapy medications should be prescribed for a postmenopausal woman, with options for an intact uterus versus after hysterectomy?

Hormone Replacement Therapy Medication Orders

For postmenopausal women with bothersome vasomotor symptoms: prescribe estrogen-only therapy (ET) for women who have had a hysterectomy, and combined estrogen plus progestogen therapy (EPT) for women with an intact uterus. 1

Algorithm for HRT Prescription

Step 1: Determine Uterine Status

Women WITHOUT a uterus (post-hysterectomy):

• Prescribe estrogen-only therapy 1, 2
• No progestogen needed since there is no endometrium to protect
• This approach has a more favorable risk profile than combined therapy, with neutral to favorable breast cancer risk 3, 4

Women WITH an intact uterus:

• Prescribe combined estrogen plus progestogen therapy 1, 2
• The progestogen is mandatory to prevent endometrial hyperplasia and malignancy from unopposed estrogen 1, 5
• Alternative: Conjugated equine estrogens (CEE) combined with bazedoxifene (BZA) where available—this provides a progestin-free option 1, 6

Step 2: Select Specific Formulations

Estrogen Options:

• Transdermal estradiol is preferred for women with moderate cardiovascular risk or thrombotic risk factors, as it has less adverse metabolic effects and lower VTE risk compared to oral formulations 1, 7, 4
• Oral conjugated equine estrogens (CEE) are acceptable but carry higher thrombotic risk 3, 4
• Use FDA-approved preparations only; avoid custom-compounded hormones 1

Progestogen Options (for women with intact uterus):

• Micronized progesterone is preferred as it does not adversely modify metabolic parameters 1
• Other progestogens (e.g., medroxyprogesterone acetate) are acceptable but may carry higher breast cancer risk with prolonged use 3
• Bazedoxifene (SERM) combined with CEE provides endometrial protection without a progestogen 1, 6

Step 3: Assess Cardiovascular Risk Before Prescribing

Age and timing considerations:

• Ideal candidates: Women <60 years old OR within 10 years of menopause onset 1
• These women have the most favorable benefit-risk profile, particularly for cardiovascular outcomes 6, 7

Risk stratification:

• High cardiovascular risk: Recommend non-hormonal therapies instead of MHT 1
• Moderate cardiovascular risk: Use transdermal estradiol with micronized progesterone (if uterus present) 1
• Low cardiovascular risk: Standard oral or transdermal formulations acceptable 1

Step 4: Verify No Contraindications

Absolute FDA contraindications include: 2

• Current, past, or suspected breast cancer
• Known estrogen-sensitive malignancies
• Undiagnosed genital bleeding
• Untreated endometrial hyperplasia
• Active or recent venous thromboembolism
• Active or recent arterial thromboembolic disease
• Untreated hypertension
• Active liver disease
• Porphyria cutanea tarda

Critical Pitfalls to Avoid

Do not add progestogen to women post-hysterectomy unless specific indications exist (residual endometriosis or endometrial tissue). Adding unnecessary progestogen increases breast cancer risk without benefit 8, 3.

Do not prescribe MHT for chronic disease prevention (cardiovascular disease, dementia, osteoporosis as primary indication) in asymptomatic women—this is explicitly not recommended 9, 2.

Smoking is a critical modifier: Women who smoke have substantially increased cardiovascular and thrombotic risk with estrogen therapy; aggressive smoking cessation must be addressed first 2.

Timing matters: Women >60 years old or >10 years past menopause have unfavorable risk-benefit profiles, particularly for cardiovascular events and stroke 1, 7.

Practical Prescribing Examples

Post-hysterectomy woman, age 52, with hot flashes:

• Transdermal estradiol 0.025-0.05 mg/day patch (apply twice weekly)
• OR oral estradiol 0.5-1 mg daily
• No progestogen needed

Woman with intact uterus, age 54, with hot flashes:

• Transdermal estradiol 0.025-0.05 mg/day patch (apply twice weekly) PLUS micronized progesterone 100-200 mg orally at bedtime
• OR conjugated equine estrogens 0.3-0.45 mg daily PLUS medroxyprogesterone acetate 1.5-2.5 mg daily
• OR conjugated equine estrogens/bazedoxifene combination tablet (where available) 1, 6

Use the lowest effective dose and employ shared decision-making to tailor formulation, route, and dosing to individual patient circumstances, risks, and treatment goals 1.